PRTCY (PureTech Health) Valuation Rank


PRTCY PureTech Health PLC PRTCY
62 GF Score
Price $17.54
GF Value $70.09
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PureTech Health Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PureTech Health Valuation Rank Related Terms

PRTCY
62GF Score
PureTech Health PLC PRTCY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PureTech Health (PRTCY) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for PRTCY:

  • Valuation Rank:
  • GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score

Get the complete analysis for PRTCY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.54
Price
$70.09
GF Value